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Abstract: Autoimmune pancreatitis (AIP) is a rare disorder whose association with coeliac disease
(CD) has never been investigated, although CD patients display a high prevalence of both endocrine
and exocrine pancreatic affections. Therefore, we sought to evaluate the frequency of CD in
patients with AIP and in further medical pancreatic disorders. The screening for CD was carried
out through the detection of tissue transglutaminase (tTG) autoantibodies in sera of patients
retrospectively enrolled and divided in four groups: AIP, chronic pancreatitis, chronic asymptomatic
pancreatic hyperenzymemia (CAPH), and control subjects with functional dyspepsia. The search for
anti-endomysium autoantibodies was performed in those cases with borderline or positive anti-tTG
values. Duodenal biopsy was offered to all cases showing positive results. One patient out of 72 (1.4%)
with AIP had already been diagnosed with CD and was following a gluten-free diet, while one case
out of 71 (1.4%) with chronic pancreatitis and one out of 92 (1.1%) control subjects were diagnosed
with de novo CD. No cases of CD were detected in the CAPH group. By contrast, a high prevalence of
cases with ulcerative colitis was found in the AIP group (13.8%). Despite a mutual association between
CD and several autoimmune disorders, our data do not support the serologic screening for CD in AIP.
Further studies will clarify the usefulness of CD serologic screening in other pancreatic disorders.
Keywords: autoimmune pancreatitis; coeliac disease; pancreatic disorders; screening
1. Introduction
Coeliac disease (CD) is an autoimmune condition affecting the small bowel mucosa of a proportion
of subjects carrying the human leukocyte antigen (HLA)-DQ2 or -DQ8 haplotypes upon gluten
ingestion [1]. Its prevalence, as assessed by serologic tests, is 0.4% in South America, 0.5% in Africa
and North America, 0.6% in Asia, and 0.8% in Europe and Oceania, with higher values in female
versus male individuals (0.6% vs. 0.4%; p < 0.001) [2]. The intestinal lesions encompass a variable
degree of villous atrophy and crypt hyperplasia, with a heavy lymphocytic infiltrate of both the
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epithelial and lamina propria layers (Figure 1) [3]. The clinical picture is multifaceted, ranging from
an overt malabsorption syndrome to apparently asymptomatic forms, with anaemia, isolated fatigue,
cryptic hypertransaminasaemia, infertility, peripheral and central neurologic disorders, osteopenia,
short stature, and dental enamel defects, being the main findings [1,4]. A gluten-free diet leads to an
almost complete recovery of both mucosal lesions and clinical features in the vast majority of cases [1].
Remarkably, owing the same genetic and/or environmental predisposing factors, CD patients are
at risk of developing further systemic or organ-specific immune-mediated disorders, with type 1
diabetes being the most prevalent and widely studied association, thus justifying the mutual serologic
screening [5]. By contrast, no information about the possible association between CD and autoimmune
pancreatitis (AIP), the immune-mediated condition affecting the exocrine component of the pancreas,
is available so far.
Nutrients 2018, 10, x FOR PEER REVIEW  2 of 11 
 
female versus male individuals (0.6% vs. 0.4%; p < 0.001) [2]. The intestinal lesions encompass a 
variable degree of villous atrophy and crypt hyperplasia, with a heavy lymphocytic infiltrate of both 
the epithelial and lamina propria layers (Figure 1) [3]. The clinical picture is multifaceted, ranging 
from an overt malabsorption syndrome to apparently asymptomatic forms, with anaemia, isolated 
fatigue, cryptic hypertransaminasaemia, infertility, peripheral and central neurologic disorders, 
osteopenia, short stature, and dental enamel defects, being the main findings [1,4]. A gluten‐free diet 
leads to an almost complete recovery of both mucosal lesions and clinical features in the vast 
majority of cases [1]. Remarkably, owing the same genetic and/or environmental predisposing 
factors, CD patients are at risk of developing further systemic or organ‐specific immune‐mediated 
disorders, with type 1 diabetes being the most prevalent and widely studied association, thus 
justifying the mutual serologic screening [5]. By contrast, no information about the possible 
association between CD and autoimmune pancreatitis (AIP), the immune‐mediated condition 
affecting the exocrine component of the pancreas, is available so far. 
 
Figure 1. Histological features of duodenal mucosa of active coeliac disease showing subtotal villous 
atrophy with crypt hyperplasia and heavy lymphocytic inflammatory infiltrate in both the epithelial 
(arrows) and lamina propria (head arrows) compartments (hematoxylin‐eosin, original 
magnification × 100). 
AIP is a rare (estimated prevalence of 0.82:100,000 [6]), chronic fibro‐inflammatory condition 
affecting the whole or a part of the gland, characterized by specific histological, radiological and 
serological aspects that disappear following a course of steroid therapy [7]. Two different types of 
AIP (type 1 and type 2) can be distinguished histologically. The first is the so called 
lymphoplasmacytic sclerosing pancreatitis displaying a dense periductal infiltration of plasma cells, 
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AIP is a rare (estimated prevalence of 0.82:100,000 [6]), chronic fibro-inflammatory condition
affecting the whole or a part of the gland, characterized by specific histological, radiological
and serological aspects that disappear following a course of steroid therapy [7]. Two different
types of AIP (type 1 and type 2) can be distinguished histologically. The first is the so called
lymphoplasmacytic sclerosing pancreatitis displaying a dense periductal infiltration of plasma cells,
mainly immunoglobulin (Ig)G4 positive, and lymphocytes, peculiar storiform fibrosis, and oblitering
venulitis (Figure 2). The second, also called idiopathic duct-centric pancreatitis, is characterized by
the presence of intraluminal and intraepithelial neutrophils in medium-sized and small ducts as well
as in acini, often leading to destruction and obliteration of the duct lumen. However, the diagnosis
of type 1 or type 2 AIP can be made even in the absence of histology by applying a combination
of two or more of the following International Consensus Diagnostic Criteria [8]: (1) characteristic
imaging features of both the parenchyma and main duct, i.e., a diffuse enlargement with delayed
enhancement of the parenchyma with a long or multiple duct strictures without marked upstream
dilatation in the typical form, while a segmental/focal enlargement with delayed enhancement of
the parenchyma with segmental short duct narrowing in the atypical one; (2) increased level of IgG4;
(3) other organ involvement, i.e., biliary duct, retroperitoneum, kidneys, salivary/lachrymal gland,
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as assessed histologically or radiologically; (4) response to steroid therapy. In those cases where
distinctive criteria cannot be identified, the diagnosis of AIP not otherwise specified is given.
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At variance with AIP, some evidence is available in the literature about the association between CD
and non-immune-mediated disorders of the exocrine pancreas. Indeed, CD patients have been found
to be at increased risk of developing both acute and chronic pancreatitis in comparison to the general
population [9,10]. In addition, patients with villous atrophy, including CD, may carry an exocrine
pancreatic insufficiency [11]. Finally, asymptomatic pancreatic hyperamylasemia, which usually
precedes the diagnosis of CD and often disappears following a gluten-free diet, has been also
described [12]. Similarly, macroamylasemia, a benign condition caused by circulating complexes
of pancreatic or salivary amylases bound to plasma proteins that cannot be cleared by the renal
glomeruli, has also been described in adulthood CD, but it possibly decreases or resolves after a strict
gluten-free diet [13].
The aim of this study, therefore, was to establish the prevalence of CD in patients suffering from
AIP by using the sera collected in the Biobank of a Tertiary Italian referral centre for pancreatic diseases.
This gave us the unique opportunity to include also patients with non-immune-mediated pancreatic
disorders, i.e., chronic pancreatitis and chronic asymptomatic pancreatic hyperenzymemia (CAPH),
as control diseased groups, other than control subjects.
2. Patients and ethods
2.1. Study Population
Four groups of adult patients not taking steroids or immunosuppressive therapy at the ti e of
blood sample harvest were enrolled in this study, as detailed below:
Group 1 ( I ). out of 259 patients diagnosed with AIP (type 1 n = 43, type 2
n = 16, n otherwi e specified n = 13) according to the International s riteria [8]
were col ected at the Pancreas Institute of the oliclinico . . ssi ( I r a,
Italy), fro Ja r . Specifica ly, 40 out of 43 with type 1 AIP (93%),
2 out of 16 with type 2 IP (12.5 ), t t r is s ecifie IP (0 ) displayed
IgG4 positivity.
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Group 2 (chronic pancreatitis). A cohort of 71 out of 492 patients diagnosed with chronic
pancreatitis from January 2012 to December 2017 was included in the study. The diagnostic criteria,
as adapted following our experience, included at least one of the following criteria: (1) presence
of pancreatic-type pain, history of acute/recurrent pancreatitis, presence of steatorrhea or diabetes,
weight loss; (2) imaging findings of pancreatic parenchyma atrophy, main pancreatic duct dilation
>6 mm and/or presence of irregularities, secondary ducts dilation, presence of pancreatic calcifications;
(3) laboratory findings of decreased level of faecal elastase-1 (<100 µg/g of stool), glycated haemoglobin
>6.5%; (4) histological features of chronic pancreatitis (loss of acinar cells, presence of interlobular
fibrosis, infiltration of inflammatory cells and relative conservation of intralobular ducts and islets) in
surgical specimens [14].
Group 3 (CAPH). This group comprised 32 out of 160 patients who were found with CAPH from
January 2012 to December 2017. The diagnosis was made when the serum levels of lipases and/or
pancreatic amylases were found above the upper normal limits (>10%) for at least three consecutive
times lasting for more than six months in the absence of pancreatic-type pain [15]. Moreover, in all cases
no lesions of the parenchyma and/or the ductal system were evident at the magnetic resonance of the
abdomen with cholangiopancreatography sequences.
Group 4 (control subjects). The serum samples of a cohort of 92 patients suffering from
functional dyspepsia, as assessed following the Rome III criteria [16], were collected from June 2012 to
December 2016. The presence of relevant co-morbidities, such as primary immunodeficiencies, cancer,
active infections or organ failure, was considered an exclusion criterion.
The demographic and clinical features of the study groups are listed in Table 1.
Table 1. Demographic and clinical features of the study population.
Autoimmune
Pancreatitis
Chronic
Pancreatitis
Chronic Pancreatic
Hyperenzymemia
Control
Subjects
Number of cases 72 71 32 92
Male/female ratio 55/17 57/14 18/14 48/44
Mean age in years (SD) 56.5 (16.9) 55.1 (13.2) 52.7 (14.6) 45.7 (18.3)
Body mass index: kg/m2
(mean ± SD) 25.1 ± 4.1 23.2 ± 5.7 24.9 ± 4.4 22.7 ± 5.2
Time from diagnosis in months
(mean ± SD) 25.4 ± 29.3 81 ± 37.5 n.a. n.a.
Concomitant autoimmune
disorders: IBD 13 (10 UC) 1 (Crohn) 0 1 (UC)
Thyroiditis 5 1 1 2
Psoriasis 3 0 0 1
Asthma 1 2 0 2
Coeliac disease 1 * 0 0 0
Rheumatic diseases 2 1 0 3
Thrombocytopenia 1 0 0 0
Abbreviation: SD: Standard Deviation; IBD: inflammatory bowel disease; n.a.: not applicable; UC: ulcerative colitis.
* case already diagnosed with coeliac disease.
The Biobank of the Pancreas Institute, Policlinico G.B. Rossi, AOUI and University of Verona, Italy
had been previously approved by the local Ethics Committee (Protocol number 5604, 2 February 2012).
This study was approved by the local Ethics Committee (Protocol number 49061, 7 July 2018) and each
enrolled patient gave written informed consent.
2.2. Screening for Coeliac Disease
Detection of tissue transglutaminase (tTG) IgA antibody was performed by using a commercial
Elisa test (Eu-tTG®IgA kit, Eurospital, Trieste, Italy; cut-off levels: negative < 9 U/mL, borderline
9–15 U/mL, positive > 15 U/mL). Patients with borderline or positive tTG IgA results underwent
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investigation for IgA anti-endomysium antibodies (EMA-IgA), which was performed by indirect
immunofluorescent technique (Eurospital), according to the manufacturer’s instructions. Sera with
low tTG IgA levels (<1 U/mL) were also evaluated by tTG IgG antibody determination (Eu-tTG®IgG
kit, Eurospital, Trieste, Italy; cut-off levels: negative < 20 U/mL, positive ≥ 20 U/mL).
Duodenal mucosal sampling was offered to all cases with positive tTG-IgA and/or EMA-IgA.
Four biopsies from the second part of the duodenum and two from the bulb were taken during upper
endoscopy for the histological examination according to the Corazza–Villanacci classification [3].
2.3. Statistical Analysis
Continuous variables were expressed as the mean and standard deviation (SD). Discrete data
were tabulated as numbers and percentages. The prevalence of CD was computed, together with its
95% exact binomial confidence intervals (95% CI) overall, for pancreatic disorders as a whole and by
diagnostic group. Stata 15 (StataCorp, College Station, TX, USA) was used for computation.
3. Results
A total of 267 serum samples harvested from 178 males and 89 females (mean age: 51.8 years,
range: 18–85) were included in this study, with 175 being from patients with pancreatic disorders and 92
from control subjects with functional dyspepsia. Worth of note, a large prevalence of males was found
in both AIP and chronic pancreatitis groups, accordingly with literature data [7,17], whereas a similar
proportion of both genders was observed in the other two groups. As shown in Table 1, one case
out of 72 patients of group 1 (1.4%), who was diagnosed with type 1 AIP, had already received the
diagnosis of CD two years earlier because of unexplained hypertransaminasemia and weight loss.
Since then, he was following a strict gluten-free diet with full recovery of laboratory and clinical
features. Therefore, his CD serology resulted negative, and a normal mucosal architecture was found at
histology (see Table 2). The radiological findings that led to the diagnosis of AIP type 1, together with
a high level of IgG4, are shown in Figure 3. The serologic screening did not detect any further case of
CD among patients affected by AIP. However, in two cases a search for tTG-IgG was carried out because
of a very low level of tTG-IgA (less than 1.0 U/mL), giving negative results (4.34 and 6.25 U/mL).
Remarkably, a consistent number of patients with AIP (13 out 72, 20.8%, of whom three had type 1 and
10 had type 2 AIP) was also affected by inflammatory bowel disease, mostly ulcerative colitis (10 out
of 13 cases, while two had indeterminate colitis and one had Crohn’s disease). Specifically, one case
was diagnosed with ulcerative colitis and AIP simultaneously, whereas the diagnosis of ulcerative
colitis preceded that of AIP by a median interval of 28 months (range, 3 to 67 months) in the remaining
patients. The vast majority of ulcerative colitis patients (eight out of 10) were not taking systemic
corticosteroids at the time of diagnosis of AIP, although they had previously undergone this therapy;
only a small proportion of them (three out of 10) was under biological agents (anti-tumour necrosis
factor monoclonal antibody). Also, one patient amongst the 71 with chronic pancreatitis (1.4%) showed
a positive value of both tTG-IgA antibodies, although at low titre (15,875 U/mL), and EMA-IgA at
1:5 dilution. The histologic examination of the duodenal biopsies showed the characteristic lesions,
thus confirming the diagnosis of CD (see Table 2), and the patient was willing to start a gluten-free
diet. When collecting his clinical history, aphthous stomatitis appeared evident. One further case was
found within the group of patients with functional dyspepsia (1.1%), displaying positivity for both
tTG-IgA (value 123 U/mL) and EMA-IgA at 1:16 dilution, thus leading to a definitive diagnosis of
CD upon the demonstration of the characteristic lesions at histologic examination of the duodenal
biopsies (see Table 2). Interestingly, she complained of infertility. An additional two cases in this
group showed borderline values of tTG-IgA (12.44 and 13.47 U/mL) but was negative for the EMA
test; hence, they did not undergo endoscopy, whereas in four cases a search for tTG-IgG was carried
out because of a very low level of tTG-IgA (less than 1.0 U/mL), giving negative results (5.42, 5.73,
5.8, 8.15 U/mL). By contrast, no cases of positive CD serology were detected among the 32 patients
with CAPH (mean value of tTG-IgA: 2.93 U/mL, range 1.276–7.537 U/mL). Therefore, as shown in
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Table 2, a total of three cases were identified to suffer from CD (two active and one treated) in the study
population; that prevalence was similar in patients with pancreatic disorders and control subjects
(overall prevalence 1.1%). Confidence intervals were consistent and ranged from 0% to about 10% in
the single diagnostic groups and up to 4% in aggregated diagnoses.
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Table 2. Cases with positive results at the serological screening with their histological findings.
N tTG IgA tTg IgG EMA Histology § Prevalence (95% CI)
Group 1 72 0 0 0 Grade A lesions * 1.4% (0.0–7.5)
Group 2 71 1 0 1 Grade B1 lesions 2.4% (0.0–7.6)
Grou 3 32 0 0 0 Not performed 0% (0.0–1 .9)
Group 4 92 1 + 2borderline 0 1 Grade B2 lesions 1.1% (0.0–5.9)
Pancreatic
disorders 175 1 0 1 − 1.1% (0.1–4.1)
Total 267 2 0 2 3 1.1% (0.2–3.2)
Abbreviations. EMA: anti-endomysium autoantibody; IgA: class A immunoglobulin; IgG: class G immunoglobulin;
N: number of cases; tTG: tissue transglutaminase. § Following the Corazza–Villanacci classification [3]. * case already
diagnosed with coeliac disease.
4. Discussion
Limited information is available about the occurrenc of exocrine pancreatic disorders during
the course of CD [18] while strong evidence demonstrates an association betw en CD and type 1
diabetes [5,19]. In fact, ap roximately 90% of patients with type 1 diabetes carry either HLA-DQ2
or -DQ8 haplotypes as compared to 0% of the g neral population [20], with those diabetic cases
homozyg us for DR3-DQ2 having a 33% risk for the presence of tTG autoantibodies [21]. Th s i
why the heterodimers encoded by these HLA haplotypes efficiently bind negat vely charged
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peptides derived from gliadin upon tTG deamidation, thus eliciting a T- and B-cell mediated
immune response [22]. This, in turn, leads to an upregulation of key pro-inflammatory molecules,
such as interferon-γ [23] and interleukin (IL)-21 [24], responsible for tissue damage. It has also been
suggested that dietary gluten could be involved in the pathogenesis of type 1 diabetes [25]. Conversely,
a gluten-free diet largely prevented diabetes onset in non-obese diabetic mice, possibly through
a modification of the gut microbiota [26].
However, autoimmune attack against the pancreas may involve not only the endocrine component,
but also the exocrine one, giving rise to AIP. This is the pancreatic manifestation of the IgG4-related
disease, whose genetic susceptibility and pathogenic mechanisms are still poorly understood [7].
Nonetheless, almost all of the candidate genes are directly or indirectly implicated in the regulation
of the immune response [7]. A further aspect supporting an autoimmune background is the large
proportion of AIP patients displaying autoantibodies, mostly against enzymes, such as lactoferrin,
carbonic anhydrases, pancreatic secretory trypsin inhibitor, and trypsinogens [27,28]. Even CD is
characterized by the presence of autoantibodies against a ubiquitous enzyme, tTG2, which, besides
being the main autoantigen and target of the anti-endomysium autoantibodies [29], catalyses
a specific and ordered deamidation of gliadin peptides, giving rise to immunodominant epitopes [22].
In addition, tTG2 seems to play a crucial role in the development of secondary autoimmunity through
a post-translational modification of additional proteins, leading to the generation of neoantigens [30].
Also of note, transgenic HLA-DQ8 mice, grown in germ-free conditions and fed a gluten-free diet,
developed acute pancreatitis after intra-peritoneal injection of cerulein, a cholecystokinin analogue that
causes hyperstimulation of the exocrine component [31]. Whether or not gliadin was then introduced
in the diet of these mice, an increased level of IgG1 (homologous of human IgG4) was observed,
together with a histological pattern resembling that of human AIP [31]. Moreover, an increased
level of serum IgG4 was documented in patients suffering from both CD and pancreatic exocrine
insufficiency [32], while an increased number of IgG4+ cells was occasionally found at the mucosal
levels of CD patients [33]. Finally, it is conceivable that the mucosal dysbiosis found in CD patients [34]
might also contribute to an autoimmune attack in close organs, like the pancreas.
Despite these hypotheses, only one case suffering from both CD and AIP has been reported so
far [35], thus we sought to investigate a putative association between these two immune-mediated
conditions, taking advantage of the sera collected at the Biobank of a Tertiary Referral centre for
pancreatic diseases. We found one patient among the 72 AIP patients who had already received the
diagnosis of CD two years earlier. Therefore, the same prevalence of CD in AIP as that of the general
population [2] was evident (1.4%). This also suggests that a gluten-free diet does not protect against
the development of AIP. One possible explanation may lie in the different genetic predisposition
since, at least in the Japanese population, an association of the DRB1*0405-DQB1*0401 haplotype with
AIP was found [36], whereas CD is associated with the HLA-DQ2 and -DQ8 ones [1,5]. Moreover,
unlike classic autoimmune diseases in which T-cells with regulatory effect are defective in number
and/or function, they are likely activated in AIP. Indeed, an increased rate of transcription factor
Forkhead box P3+CD4+CD25+ T-cells in both pancreatic tissue [37] and peripheral blood [38] was found
in AIP patients, together with upregulation of two cytokines with modulatory functions, i.e., IL-10 and
transforming growth factor-β [7]. These seem to be key molecules since the former contributes to IgG4
class switching [39], while the latter is involved in the development of fibrosis [40].
At variance with CD, a strong association between AIP and IBD (18.0% of cases), mostly
ulcerative colitis (13.9%), has been found in our cohort of Caucasian patients, thus confirming previous
reports [41,42]. However, the prevalence was higher than that found in either an American [41]
or an Asiatic [42] study, where a frequency of 5.6% and 5.8%, respectively, was found. Likewise,
both have a retrospective design and a similar sample size (71 and 104 AIP cases, respectively) [41,42].
However, the tools applied for the diagnosis of AIP were different, since the HISORt criteria for
AIP [43] were used in the former, whereas the Asian Diagnostic Criteria for AIP [44] were used in
the latter, thus possibly affecting the final results. The discrepancy may also be partly related to
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ethnic differences and to the relatively small number of patients recruited. Interestingly, the course of
ulcerative colitis was worst in those suffering from both diseases since, during the follow-up period of
10 years, 33.3% of patients underwent a colectomy versus none of those suffering from ulcerative colitis
alone [42]. Finally, although Berkson’s bias (patients with two uncommon diseases are more likely
to be referred to a tertiary medical centre than patients with just one such disease) [45] could have
inflated the magnitude of this association, our data strongly suggest that the AIP and ulcerative colitis
are related to some degree whose extent deserves further investigation.
As far as the non-immune-mediated pancreatic disorders are concerned, it is widely acknowledged
that both functional and anatomical changes of the gland may be caused by or coexist with CD [18].
A Swedish register study, indeed, found an increased risk of both acute and chronic pancreatitis
in patients with adulthood CD during the observational period of 1964 to 2003 [9]. Furthermore,
it was estimated that over 20% of patients with CD have defective exocrine pancreatic function [10].
This seems to be related to an impaired secretion of cholecystokinin pancreozymin secondary to
enteropathy and/or malnutrition, since normalization of both intestinal mucosa and nutritional status
restores the secretion of digestive hormones and enzymes [46]. Nevertheless, no information on the
prevalence of CD in non-immune-mediated pancreatic disorders is available so far. We found one case
in the chronic pancreatitis group (1.4%) and one in the control subject group (1.1%), again overlapping
with the prevalence in the general population [2]. Thus, despite a relationship between CD and
pancreatic disorders having been demonstrated, the opposite does not seem true. Accordingly, we did
not find any positivity at the serologic screening for CD in the CAPH group, even though an abnormal
elevation of serum amylase and/or lipase was found in CD patients but disappeared upon a course of
gluten-free diet [12].
Obviously, our study has strengths and weaknesses. A point of strength is that this is the first study
investigating the prevalence of CD in patients suffering from pancreatic disorders, whereas the studies
published so far did the opposite. Moreover, if we consider that AIP is a rare and difficult-to-diagnose
condition, the large sample size available, together with the appropriateness of the diagnosis, put us in
a privileged situation where the putative higher prevalence of CD in this clinical setting might have
been demonstrated, if there was any. The limitations include the retrospective design and the small
sample size (and thus the relatively large confidence intervals) of the CAPH and chronic pancreatitis
groups in comparison with the overall institutional cohorts due to the low level of willingness to give
serum samples for future unknown studies, whereas the lack of sex and age matching among AIP and
chronic pancreatitis patients with CAPH and control cases was largely expected [7,47]. In addition,
serum IgG or IgG4 levels were not available in non-AIP groups because they are not routinely measured.
Despite these limitations, our cohort of 72 patients with AIP represents one of the largest single-centre
experiments to date.
5. Conclusions
In summary, our findings suggest that there is a low probability of there being an association
of CD with AIP, thus serological screening for CD is not recommended in patients with AIP.
By contrast, a strong association between AIP and ulcerative colitis appears evident. AIP is a relatively
“new” diagnostic entity, thus further prospective and multicentre studies are needed to confirm the
conclusions of this study.
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